npj Vaccines

Article	Citations
Recent advances and perspectives on the development of circular RNA cancer vaccines	283
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection	214
Ad26.M.Env ZIKV vaccine protects pregnant rhesus macaques and fetuses against Zika virus infection	204
A protein subunit vaccine elicits a balanced immune response that protects against Pseudomonas pulmonary infection	183
Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging	162
Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines	154
Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials	127
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	123
Author Correction: SPA14 liposomes combining saponin with fully synthetic TLR4 agonist provide adjuvanticity to hCMV vaccine candidate	103
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines	101
A broad spectrum Shigella vaccine based on VirG53–353 multiepitope region produced in a cell-free system	91
mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice	90
A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI	89
Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model	89
T cell independent antibody responses with class switch and memory using peptides anchored on liposomes	84
Understanding the rationales and information environments for early, late, and nonadopters of the COVID-19 vaccine	77
Author Correction: A randomized study to evaluate the safety and immunogenicity of a pentavalent meningococcal vaccine	73
Modeling the persistence of 4CMenB vaccine protection against real world meningococcal B disease in adolescents	72
Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity	72
Implications of the apparent extinction of B/Yamagata-lineage human influenza viruses	66
Duck CD40L as an adjuvant enhances systemic immune responses of avian flavivirus DNA vaccine	58
Persistence of hepatitis E vaccine-induced antibody response across different dosage schedules and baseline serostatus	56
Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine	55
A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs	54
Mpox mRNA-1769 vaccine inhibits orthopoxvirus replication at intranasal, intrarectal, and cutaneous sites of inoculation	54

Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis	54
Evaluation of adenoviral vector Ad19a encoding RSV-F as novel vaccine against respiratory syncytial virus	53
Humoral response to anti-SARS-CoV-2 vaccine in breastfeeding mothers and mother-to-infant antibody transfer through breast milk	52
Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2	52
Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity	51
Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models	51
Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern	50
Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge	50
Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis	50
Immunological correlates of protection following vaccination with glucan particles containing Cryptococcus neoformans chitin deacetylases	48
Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine	47
Intranasal multivalent adenoviral-vectored vaccine protects against replicating and dormant M.tb in conventional and humanized mice	47
Author Correction: “World in motion” – emulsion adjuvants rising to meet the pandemic challenges	45
Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort	44
Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic	44
YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge	42
Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination	40
Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques	40
Cationic-nanogel nasal vaccine containing the ectodomain of RSV-small hydrophobic protein induces protective immunity in rodents	40
Antiviral effect of SARS-CoV-2 N-specific CD8+ T cells induced in lungs by engineered extracellular vesicles	39
PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application	39
Identifying a causal link between prolactin signaling pathways and COVID-19 vaccine-induced menstrual changes	39
Assessing immunogenicity barriers of the HIV-1 envelope trimer	38
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle	38
Insights into the protective immune response by immunization with full-length recombinant TprK protein: cellular and humoral responses	36
Identification of the flavivirus conserved residues in the envelope protein hinge region for the rational design of a candidate West Nile live-attenuated vaccine	35
Cross-protection and cross-neutralization capacity of ancestral and VOC-matched SARS-CoV-2 adenoviral vector-based vaccines	35
Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children	35
The full health, economic, and social benefits of prospective Strep A vaccination	34
Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate	34
No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines	33
Absolute quantitation of binding antibodies from clinical samples	32
Efficacy and safety in mice of repeated, lifelong administration of an ANGPTL3 vaccine	32
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys	32
Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets	31
Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses	31
mRNA vaccine encoding Gn provides protection against severe fever with thrombocytopenia syndrome virus in mice	31
Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis	31
Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine	31
Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques	30
Rational design of innate defense regulator peptides as tumor vaccine adjuvants	30
Author Correction: Protective antibody response following oral vaccination with microencapsulated Bacillus Anthracis Sterne strain 34F2 spores	30
Author Correction: Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer	30
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants	30
Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice	30
MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge	29
Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells	29
Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore	29
Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant	28
Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines	28

Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates	28
A single intranasal dose of human parainfluenza virus type 3-vectored vaccine induces effective antibody and memory T cell response in the lungs and protects hamsters against SARS-CoV-2	27
Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination	27
Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens	27
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization	26
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine	26
Influence of individuals’ determinants including vaccine type on cellular and humoral responses to SARS-CoV-2 vaccination	26
Vaccine-induced time- and age-dependent mucosal immunity to gastrointestinal parasite infection	26
Progress with COVID vaccine development and implementation	26
Reverse development of vaccines against antimicrobial-resistant pathogens	26
Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study	25
Prospective cohort study evaluating the association between influenza vaccination and neurodegenerative diseases	25
A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses	25
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines	25
Improving precision of vaccine efficacy evaluation using immune correlate data in time-to-event models	25
Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform	25
BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice	25
MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates	24
Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Qβ virus-like particles	24
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice	24
Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses	24
Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunity	24
Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine	24
Interplay of diverse adjuvants and nanoparticle presentation of native-like HIV-1 envelope trimers	23
The dengue-specific immune response and antibody identification with machine learning	23
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity	23
Benefit of COVID-19 vaccination accounting for potential risk compensation	22
Factors influencing long-term persistence of anti-HBs after hepatitis B vaccination	22
Combined effects of glycan chain length and linkage type on the immunogenicity of glycoconjugate vaccines	22
Assessing acute kidney injury risk after COVID vaccination and infection in a large cohort study	22
A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3–17 years	22
Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein	22
Rational development of a combined mRNA vaccine against COVID-19 and influenza	22
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action	21
The rapid progress in COVID vaccine development and implementation	21
Haplotype-resolved de novo assembly of the Vero cell line genome	21
Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection	21
CircRNA based multivalent neuraminidase vaccine induces broad protection against influenza viruses in mice	20
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	20
Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2	20
RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses	20
SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non-human primates	20
Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines	20
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic	20
Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination	20
Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development	20
Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities	20
Resistance to COVID-19 vaccination and the social contract: evidence from Italy	20
Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies	20
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine	19
mRNA-LNP vaccination-based immunotherapy augments CD8+ T cell responses against HPV-positive oropharyngeal cancer	19
Protein engineering strategies for rational immunogen design	19
Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report	19
Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients	19
Rapid development of attenuated IBV vaccine candidates through a versatile backbone applicable to variants	19
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza	19
Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant binding	19
Mapping global public perspectives on mRNA vaccines and therapeutics	19
A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer’s disease in 3xTg mice	19
Antigenic comparison of the neuraminidases from recent influenza A vaccine viruses and 2019–2020 circulating strains	19
Emerging vaccine strategies against the incessant pneumococcal disease	19
A highly stable lyophilized mRNA vaccine for Herpes Zoster provides potent cellular and humoral responses	18
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year	18
COVID-19 vaccine refusal is driven by deliberate ignorance and cognitive distortions	18
Production of an immunogenic trivalent poliovirus virus-like particle vaccine candidate in yeast using controlled fermentation	18
Neoantigen cancer vaccine augments anti-CTLA-4 efficacy	18
A functional enzymatic assay as potential readout for a clinical trial of a schistosomiasis vaccine	18
The road to approved vaccines for respiratory syncytial virus	18
RETRACTED ARTICLE: Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies	18
Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome	17
A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax	17
Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV—workshop report	17
Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230	17
Virus-based vaccine vectors with distinct replication mechanisms differentially infect and activate dendritic cells	17
Reply to: mRNA COVID-19 vaccinations are not associated with RVO development 21 days and 12 weeks after vaccination	17
Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum	17
Immune response against SARS-CoV-2 variants: the role of neutralization assays	17
Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact	17
Modeling the potential health impact of prospective Strep A vaccines	17
Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2	16

Extended interval BNT162b2 vaccination enhances peak antibody generation	16
Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice	16
Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice	16
High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers	16
Preimmunization correlates of protection shared across malaria vaccine trials in adults	16
Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data	15
Development of antibody-dependent cellular cytotoxicity in response to recombinant and live-attenuated herpes zoster vaccines	15
Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern	15
CD4 T cell epitope abundance in ferritin core potentiates responses to hemagglutinin nanoparticle vaccines	15
Full efficacy and long-term immunogenicity induced by the SARS-CoV-2 vaccine candidate MVA-CoV2-S in mice	15
Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination	15
Centrin-deficient Leishmania mexicana confers protection against Old World visceral leishmaniasis	15
Assembly-defective Tembusu virus ectopically expressing capsid protein is an approach for live-attenuated flavivirus vaccine development	15
Rapid generation of Shigella flexneri GMMA displaying natural or new and cross-reactive O-Antigens	15
Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant	15
Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets	15
Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children	15
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition	14
OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humans	14
Immunization with a Trypanosoma cruzi cyclophilin-19 deletion mutant protects against acute Chagas disease in mice	14
Correlates of immunity to Group A Streptococcus: a pathway to vaccine development	14
Establishing RTS,S/AS01 as a benchmark for comparison to next-generation malaria vaccines in a mouse model	14
Author Correction: A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques	14
Author Correction: Selectively targeting haemagglutinin antigen to chicken CD83 receptor induces faster and stronger immunity against avian influenza	14
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth	14
Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination	14
Impact of host genetic polymorphisms on response to inactivated influenza vaccine in children	14
Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates	13
A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark	13
MVA-based vaccines are protective against lethal eastern equine encephalitis virus aerosol challenge in cynomolgus macaques	13
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming	13
Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera	13
High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters	13
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine	13
Antigen self-anchoring onto bacteriophage T5 capsid-like particles for vaccine design	13
The role of correlates of protection in overcoming barriers to vaccine development and demonstrating efficacy	13
Immunization-induced antigen archiving enhances local memory CD8+ T cell responses following an unrelated viral infection	13
Leishmania tarentolae as a platform for the production of vaccines against viral pathogens	13
Author Correction: The direct effect of SARS-CoV-2 virus vaccination on human ovarian granulosa cells explains menstrual irregularities	13
Author Correction: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax	13
Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine	13
Replicon particle vaccination induces non-neutralizing anti-nucleoprotein antibody-mediated control of Crimean-Congo hemorrhagic fever virus	13
Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge	13
Author Correction: The dengue-specific immune response and antibody identification with machine learning	13
Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen	12
Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice	12
Optimization of an alum-anchored clinical HIV vaccine candidate	12
Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens	12
Strep A: challenges, opportunities, vaccine-based solutions and economics	12
Systematic review and meta-analysis of the factors affecting waning of post-vaccination neutralizing antibody responses against SARS-CoV-2	12
Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen	12
The immunological interplay between vaccination and the intestinal microbiota	12
Replicating RNA vaccine confers durable immunity against Crimean Congo hemorrhagic fever virus challenge in mice	12
A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation	12
Sustained antigen delivery improves germinal center reaction and increases antibody responses in neonatal mice	12
Establishment of isotype-switched, antigen-specific B cells in multiple mucosal tissues using non-mucosal immunization	12
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus	12
Both chimpanzee adenovirus-vectored and DNA vaccines induced long-term immunity against Nipah virus infection	12
Author Correction: Enhanced attenuation of chikungunya vaccines expressing antiviral cytokines	12
Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses	12